ICC Capital Management’s Biogen BIIB Stock Holding History

ICC Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$1.29M	Buy	+3,045	New	+$1.2M	0.17%	177

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

ICC Capital Management's BIIB Position: Q1 2015 in Review

ICC Capital Management opened a new position in Biogen (BIIB) in Q1 2015: 3,045 shares worth $1.29M. The stake represents 0.17% of the portfolio and ranks #177 among its holdings.

967 funds tracked by Wall St. Rank hold BIIB as of Q1 2015.

ICC Capital Management held 3,045 shares of Biogen worth $1.29M as of Q1 2015.
Biogen was a new ICC Capital Management position in Q1 2015.
Biogen made up 0.17% of ICC Capital Management's portfolio in Q1 2015, its #177 holding.
967 funds tracked by Wall St. Rank held Biogen as of Q1 2015.

Based on ICC Capital Management's 13F filing for Q1 2015, filed 13 May 2015.